(Another) activist attack on Alexion, as Paul Singer-founded hedge fund calls for biotech to sell itself
In December, Alexion was forced to issue a highly unusual statement: No, they told investors, the company is not for sale and, no, they have not received any offers.
“It is highly unusual, if not unprecedented, for a biopharmaceutical company of our size and maturity to proactively launch a sale process,” they wrote. “We do not believe this approach is the best path for driving shareholder value.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
